VitalConnect acquisition: IRTC targets 15% EBITDA margin by 2027
IRTC said its VitalConnect acquisition is meant to fully address the MCT market, leveraging differentiated technology and expanding its product portfolio. The company reiterated a 15% EBITDA margin goal for 2027 and continued innovation investment.
The conference highlighted the VitalConnect acquisition as a key step toward fully addressing the MCT market, using differentiated technology and broadening the product portfolio. Financial targets remain centered on growth, with a 15% EBITDA margin goal for 2027 and continued investment in innovation.